Telix Pharmaceuticals's EBIT per Share for the
six
months ended in Dec. 2025 was $0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11.
During the past 12 months, the average EBIT per Share Growth Rate of Telix Pharmaceuticals was -66.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Telix Pharmaceuticals's EBIT per Share or its related term are showing as below:
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Telix Pharmaceuticals was -11.30% per year. The lowest was -155.90% per year. And the median was -88.15% per year.
TLX's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Telix Pharmaceuticals (NAS:TLX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Telix Pharmaceuticals EBIT per Share Related Terms
Telix Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (TLX) has a EBIT per Share of $0.11 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Telix Pharmaceuticals and its competitors. According to the industry distribution chart, Telix Pharmaceuticals ranks #999999 out of 1181 companies in the Biotechnology industry.
Is Telix Pharmaceuticals' EBIT per Share too high?
Telix Pharmaceuticals' current EBIT per Share is $0.11. The Biotechnology industry median EBIT per Share is 15.50. Telix Pharmaceuticals' value of $0.11 is 99.3% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #999999 out of 1181 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #999999 out of 1181 companies for EBIT per Share. This places Telix Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 15.50. Telix Pharmaceuticals' value of $0.11 is 99.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current EBIT per Share of $0.11 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current EBIT per Share is $0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $29.12, compared to a current price of $11.53 — trading 60.4% below its estimated fair value. The current EBIT per Share is $0.11 and 99.3% below the Biotechnology industry median of 15.50. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current EBIT per Share is $0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.53 is trading 60.4% below its estimated GF Value™ of $29.12.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
EBIT per Share: $0.11
GF Value™: $29.12 vs. price of $11.53 (60.4% below fair value)
Industry Position: 99.3% below the Biotechnology median (#999999 of 1181)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
